Skip to main content

Table 5 Number of non-susceptible (i.e. intermediate or resistant) isolates detected among 309 pneumococcal isolates from parents of children under 5 years of age in Western Kenya, by serotype included in the PCV10 or PCV13 vaccine* [N (%)]

From: High Streptococcus pneumoniae colonization prevalence among HIV-infected Kenyan parents in the year before pneumococcal conjugate vaccine introduction

 

Serotype

 
 

1

3

4

6A

6B

7 F

9 V

14

18C

19A

19 F

23 F

Any PCV10

Any PCV13

Number of isolates

2

39

7

16

8

4

6

4

10

1

32

25

98

154

Antibiotic

              

Penicillin

1 (50)

38 (97)

3 (43)

9 (56)

8 (100)

4 (100)

4 (66)

4 (100)

3 (30)

1 (100)

31 (97)

20 (80)

78 (80)

125 (81)

Chloramphenicol

0

0

0

0

0

0

2 (33)

0

0

0

0

1 (4)

3 (3)

3 (2)

Levofloxacin

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Erythromycin

0

1 (3)

0

0

0

0

0

0

0

0

1 (3)

0

1 (1)

2 (1)

Ceftriaxone

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Tetracycline

0

26 (66)

1 (14)

0

1 (13)

0

2 (33)

4 (100)

0

0

4 (13)

1 (4)

13 (13)

39 (25)

Cotrimoxazole

2 (100)

37 (97)

7 (100)

16 (100)

8 (100)

4 (100)

6 (100)

4 (100)

8 (80)

1 (100)

25 (78)

25 (100)

89 (91)

143 (93)

Clindamycin

0

1 (3)

0

0

0

0

0

0

0

0

0

0

0

1 (1)

  1. PCV10 Ten-valent pneumococcal conjugate vaccine (serotypes 1, 4, 5, 6B, 7 F, 9 V, 14, 18C, 19 F, 23 F), PCV13 Thirteen-valent pneumococcal conjugate vaccine (serotypes 1, 3, 4, 5, 6A, 6B, 7 F, 9 V, 14, 18C, 19A, 19 F, 23 F)
  2. aNo serotype 5 isolates were detected